Drug Profile
Research programme: G-protein coupled receptor 3 antagonists - Galapagos
Alternative Names: GPR3 inhibitors programmeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Small molecules
- Mechanism of Action Amyloid beta-protein precursor inhibitors; G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in Belgium
- 13 Feb 2009 Early research in Alzheimer's disease in Belgium (unspecified route)